NIDDK Digital Health Technology for Type 2 Diabetes Management

NIDDK Digital Health Technology for Type 2 Diabetes

Funds NIDDK research on digital health interventions for type two diabetes care and behavior change.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) issued RFA-DK-26-315 on September 17, 2025, to fund R01 clinical trial grants examining the efficacy of digital health technology (DHT) interventions for managing type 2 diabetes. The program is specifically interested in continuous glucose monitoring (CGM), telemedicine with virtual coaching, connected digital devices such as smartwatches and activity monitors, mobile health (mHealth) applications, text messaging, patient portals, and peer-support digital interventions. Multimodality DHT interventions — for example, CGM combined with virtual remote continuous care — are of particular interest to NIDDK's program staff. Applications studying automated insulin delivery systems including artificial pancreas technology, technologies exclusively used in T1D, or mechanistic clinical trials are explicitly non-responsive to this NOFO.

RFA-DK-26-315 funds R01 grants and requires a clinical trial — applicants without a trial component will be deemed non-responsive. NIDDK intends three awards per cycle. Direct costs are $1.5 million in FY2026, $3.0 million per year in FY2027 through FY2030, and $1.5 million in FY2031, reflecting a standard five-year maximum project period with front-loaded and back-loaded budgets. Application budgets are not capped but must reflect actual needs. The RFA has two cycles: the first deadline of November 7, 2025, has passed; the FY2027 deadline is October 6, 2026, with scientific merit review in March 2027, Advisory Council review in May 2027, and earliest start date of July 2027. Only new applications are accepted; renewals are not permitted.

Foreign organizations are ineligible and foreign components are not allowed. Eligible applicants include US universities, nonprofits, for-profit organizations including small businesses, and government entities. The program is funded under Assistance Listing 93.847. Scientific contact is Dr. Henry Burch (henry.burch@nih.gov, 301-827-0827) and grants management contact is Natasha Kimes (natasha.loveless@nih.gov). Competitive applications will demonstrate rigorous trial designs, validated DHT outcome measures, and populations that reflect the demographic burden of T2D in the United States.